JP5833126B2 - ウマ科動物の羊水由来の多分化能幹細胞及びそれを製造する方法 - Google Patents
ウマ科動物の羊水由来の多分化能幹細胞及びそれを製造する方法 Download PDFInfo
- Publication number
- JP5833126B2 JP5833126B2 JP2013528119A JP2013528119A JP5833126B2 JP 5833126 B2 JP5833126 B2 JP 5833126B2 JP 2013528119 A JP2013528119 A JP 2013528119A JP 2013528119 A JP2013528119 A JP 2013528119A JP 5833126 B2 JP5833126 B2 JP 5833126B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- stem cells
- amniotic fluid
- cultured
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004381 amniotic fluid Anatomy 0.000 title claims description 64
- 210000002894 multi-fate stem cell Anatomy 0.000 title claims description 37
- 238000004519 manufacturing process Methods 0.000 title claims description 20
- 210000004027 cell Anatomy 0.000 claims description 118
- 241000283073 Equus caballus Species 0.000 claims description 88
- 210000000130 stem cell Anatomy 0.000 claims description 63
- 239000002609 medium Substances 0.000 claims description 54
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 34
- -1 CD31 Proteins 0.000 claims description 30
- 230000001900 immune effect Effects 0.000 claims description 29
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 24
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 20
- 102100032912 CD44 antigen Human genes 0.000 claims description 20
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 20
- 239000012091 fetal bovine serum Substances 0.000 claims description 20
- 102100037241 Endoglin Human genes 0.000 claims description 19
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 19
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 19
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 18
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 18
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 18
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 17
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 17
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 17
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 17
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 17
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 17
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 17
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 claims description 17
- 101000622137 Homo sapiens P-selectin Proteins 0.000 claims description 17
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 17
- 102100033467 L-selectin Human genes 0.000 claims description 17
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims description 17
- 102100023472 P-selectin Human genes 0.000 claims description 17
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 17
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 17
- 210000003716 mesoderm Anatomy 0.000 claims description 17
- 210000002889 endothelial cell Anatomy 0.000 claims description 15
- 230000010261 cell growth Effects 0.000 claims description 13
- 230000001976 improved effect Effects 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 210000004748 cultured cell Anatomy 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 description 36
- 238000000034 method Methods 0.000 description 24
- 210000002449 bone cell Anatomy 0.000 description 21
- 210000001612 chondrocyte Anatomy 0.000 description 20
- 210000001789 adipocyte Anatomy 0.000 description 18
- 238000010186 staining Methods 0.000 description 18
- 238000012258 culturing Methods 0.000 description 15
- 239000003550 marker Substances 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 11
- 210000004504 adult stem cell Anatomy 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 210000003981 ectoderm Anatomy 0.000 description 11
- 210000001900 endoderm Anatomy 0.000 description 11
- 239000008188 pellet Substances 0.000 description 11
- 230000006698 induction Effects 0.000 description 10
- 210000002435 tendon Anatomy 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- JKYKXTRKURYNGW-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(O)(=O)=O)=C2 JKYKXTRKURYNGW-UHFFFAOYSA-N 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 210000005087 mononuclear cell Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 241000283086 Equidae Species 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 5
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 5
- 239000007640 basal medium Substances 0.000 description 5
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 5
- 238000002659 cell therapy Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000000663 muscle cell Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000012997 ficoll-paque Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 3
- 241000283087 Equus Species 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 3
- 241001331845 Equus asinus x caballus Species 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 230000004072 osteoblast differentiation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229950003937 tolonium Drugs 0.000 description 3
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 3
- 241001494467 Asinus Species 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000777300 Congiopodidae Species 0.000 description 2
- 241000283070 Equus zebra Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001494463 Hippotigris Species 0.000 description 2
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 2
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 2
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 102000046949 human MSC Human genes 0.000 description 2
- 229940116978 human epidermal growth factor Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001074 muscle attachment cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
[本発明1001]
ウマ科動物の羊水から分離した幹細胞をEGM-2(Endothelial cell Growth Medium-2)培地で培養する第1のステップと
培養された細胞を回収する第2のステップ
を含み、
次のような特性を示しかつ培養前の幹細胞より均質度が改善されたウマ科動物の羊水由来多分化能幹細胞の製造方法:
(a)ヒトマーカーのCD19、CD20、CD28、CD31、CD34、CD38、CD41a、CD62L、CD62P及びCD200に対して全て陰性の免疫学的特性を示し、ヒトマーカーのCD44、CD90及びCD105に対して全て陽性の免疫的特性を示し、
(b)外胚葉、中胚葉又は内胚葉由来細胞に分化する能力を持ち、かつ
(c)未分化の状態で14継代以上培養される能力を持つ。
[本発明1002]
第1のステップにてウマ科動物の羊水から分離された幹細胞が、密度勾配溶液を用いて遠心分離した後、中間層である細胞層から抽出されることが特徴である、本発明1001の製造方法。
[本発明1003]
第1のステップが、ウマ科動物の羊水から分離した幹細胞をEGM-2(内皮細胞成長培地-2)培地で付着培養するのが特徴である、本発明1001の製造方法。
[本発明1004]
第1のステップにてEGM-2培地にウシ胎児血清(FBS)を添加して培養するのが特徴である、本発明1001の製造方法。
[本発明1005]
第1のステップにて培養した細胞を、DMEM(ダルベッコ変法イーグル培地)に交換して培養するステップをさらに追加することが特徴である、本発明1001の製造方法。
[本発明1006]
前記DMEM培地が、ウシ胎児血清(FBS)を含有する低グルコースDMEM培地であることが特徴である、本発明1001の製造方法。
[本発明1007]
ウマ科動物の羊水を準備する第1のステップと、
前記羊水から、ヒトマーカーのCD19、CD20、CD28、CD31、CD34、CD38、CD41a、CD62L、CD62P及びCD200に対して全て陰性の免疫学的特性を示し、ヒトマーカーのCD44、CD90及びCD105に対して全て陽性の免疫学的特性を示す多分化能幹細胞を分離する第2のステップ
を含み、次のような特性を示す均質なウマ科動物の羊水由来多分化能幹細胞の製造方法:
(a)外胚葉、中胚葉又は内胚葉由来細胞に分化する能力を持ち、かつ
(b)未分化の状態で14継代以上培養される能力を持つ。
[本発明1008]
第2のステップにて免疫学的分離が、前記ヒトマーカーに対して異なる種(species)の間でも交差反応する抗体を用いることが特徴である、本発明1007の製造方法。
[本発明1009]
次のような特性を持つウマ科動物の羊水由来多分化能幹細胞:
(a)ヒトマーカーのCD19、CD20、CD28、CD31、CD34、CD38、CD41a、CD62L、CD62P及びCD200に対して全て陰性の免疫学的特性を示し、ヒトマーカーのCD44、CD90及びCD105に対して全て陽性の免疫的特性を示し、
(b)外胚葉、中胚葉又は内胚葉由来細胞に分化する能力を持ち、かつ
(c)未分化状態で14継代以上培養される能力を持つ。
[本発明1010]
前記中胚葉由来細胞が、軟骨細胞、骨細胞、脂肪細胞、腱細胞又は筋細胞であることが特徴である、本発明1009の多分化能幹細胞。
[本発明1011]
前記ウマ科動物が、シマウマ、ウマ、ラバ、およびロバよりなる群から選択される一つであることが特徴である、本発明1009の多分化能幹細胞。
[本発明1012]
本発明1009〜1011のいずれかの多分化能幹細胞を軟骨細胞分化培地で培養することを特徴とする、多分化能幹細胞を軟骨細胞に分化させる方法。
[本発明1013]
本発明1009〜1011のいずれかの多分化能幹細胞をデキサメタゾン、β-グリセロリン酸及びアスコルビン酸-2-リン酸を含有した培地で培養することを特徴とする、多分化能幹細胞を骨細胞に分化させる方法。
[本発明1014]
本発明1009〜1011のいずれかの多分化能幹細胞をデキサメタゾン、インドメタシン、3-イソブチル-メチルキサンチン及びインスリンを含有した培地で培養することを特徴とする、多分化能幹細胞を脂肪細胞に分化させる方法。
[本発明1015]
本発明1001〜1008のいずれかの方法によって製造された多分化能幹細胞、又は本発明1009〜1011のいずれか一項に記載された多分化能幹細胞、又はこれから分化した細胞を有効成分に含有する、細胞治療剤。
[本発明1016]
ウマ科動物の骨関節炎の治療用、ウマ科動物の骨欠失疾患治療用、ウマ科動物の脂肪組織形成用、ウマ科動物の腱組織形成用及びウマ科動物の筋肉組織の形成用の、本発明1015の細胞治療剤。
(a)ヒトマーカーのCD19、CD20、CD28、CD31、CD34、CD38、CD41a、CD62L、CD62P及びCD200に対して全て陰性の免疫学的特性を示し、ヒトマーカーのCD44、CD90及びCD105に対して全て陽性の免疫的特性を示し、
(b)外胚葉、中胚葉又は内胚葉由来細胞に分化する能力を持ち、かつ
(c)未分化状態で14継代以上培養される能力を持つ。
(a)外胚葉、中胚葉又は内胚葉由来細胞に分化する能力を持ち、かつ
(b)未分化状態で14継代以上培養される能力を持つ。
(a)ヒトマーカーのCD19、CD20、CD28、CD31、CD34、CD38、CD41a、CD62L、CD62P及びCD200に対して全て陰性の免疫学的特性を示し、ヒトマーカーのCD44、CD90及びCD105に対して全て陽性の免疫的特性を示し、
(b)外胚葉、中胚葉又は内胚葉由来細胞に分化する能力を持ち、かつ
(c)未分化状態で14継代以上培養される能力を持つ。
1-1:ウマの羊水収集
ウマの羊水は韓国所在の馬舎にある馬小屋で、サラブレッドの雌馬(thoroughbred mares)が分娩した際に獲得した。分娩時の雌馬は非常に鋭敏で、胎盤を包んでいる皮膚は雌馬が容易に破裂させることが出来るので、雌馬を刺激しないように慎重に羊水を採取した。採取した全ての羊水は、皮膚の破裂前に30mlの注射器、18-ゲージの注射針で収集した。汚染を防ぐために、注射器、手袋を使用し、全ての手順は迅速に行われた。サンプルは12時間の間、摂氏4度を維持して研究室に移した。平均的に得られた羊水の量は約30mlであった。
MSCは、単核細胞から分離されることが従来の研究で知られており、(Colter DC et al.、Proc.Natl.Acad.Sci.USA.97(7):3213-8、2000)単核細胞(MNC)は、次のような方法で分離した。初めに、明確なバフィーコート層を得るために、ウマの羊水にリン酸緩衝塩類溶液(PBS)を1:1(v:v)の割合で補充して希釈した。希釈されたサンプルをFicoll-Paque密度勾配溶液 (GE Healthcare社、米国)を用いて、2500rpmで20分間遠心分離した。単核細胞を得た後、血球及び血小板を除去するためにPBSで数回洗浄して単核細胞を分離した。
実施例1−2による単核細胞をフィブロネクチンでコーティングされた100mm培養皿(Nunc社、米国)に分注して5%CO2、37℃の条件で培養した。フィブロネクチンは、細胞がプレートによく付着できるように使用した。培養培地は、20%FBS(ウシ胎児血清、Gibco-BRL、米国)及び内皮細胞成長培地-2 SingleQuot(EGM-2 Single Quot; Lonza社、スイス)を含有する内皮細胞の基礎培地(Endothelial cell Basal Medium; EBM 、Lonza社、スイス)を使用した。基礎培地に含有されている数種類の成長因子(ヒト塩基性線維芽細胞成長因子; h-bFGF、血管内皮増殖因子; VEGF、長鎖R3インスリン様成長因子; R3-IGF、ヒト上皮成長因子;h-EGF)は、初期の細胞の成長を促進させる役割を果たした。
多分化能幹細胞(MSC)を始めとする幹細胞は、自己再生能力があり、多くの場合、自己再生能力は胚性幹細胞(ESC)、造血幹細胞(HSC)、癌幹細胞(CC)のような継続的で安定した増殖率と関連している(Reya T. et al.、Nature、Nov 1、414(6859):105-11、2001)。したがって、eAF-MSCの成長効率と増殖の潜在性を測定するために、実施例1-3で得られた幹細胞のCPDL(累積集団倍加数)の値を測定した。
次のような式で表される。
CPDL = ln(Nf / Ni)/ ln2
(Ni:初期に分注した細胞数、Nf:最終細胞数)
一般的に、ヒトMSCは区別される表面抗原マーカーを示す。細胞治療国際協会(International Society of Cellular Therapy)によると、一般的にヒトMSCはヒトマーカーのCD73、CD44、CD90及びCD105に陽性発現を示し、ヒトマーカーのCD11b、CD14、CD18、CD79a、CD34、CD45、及びHLA-DRに陰性発現を示す(Dominici M. et al.、Cytoherapy、8(4):315-7、2006)。したがって、eAF-MSCに対してフローサイトメトリー分析をして、免疫表現型を調べるために以下の実験を行った。
eAF-MSCの特性を検証するために、三血球系分化の分析を行った。一般的にMSCは生体外(in vitro)で軟骨細胞、骨細胞及び脂肪細胞に分化することができる。したがって、eAF-MSCの分化が可能か否かを検証するために、それぞれの系統に合った培地で培養した。
軟骨細胞への分化が可能か否かを調べるために、実施例1-3の方法で得られたeAF-MSCを15ml ポリプロピレン・チューブに分注して、遠心分離しペレットにした。ペレットは外観が白く透明であるが、そのペレットを37℃、5%二酸化炭素の条件下でインキュベーターにおいて1mlの軟骨細胞分化誘導培地(Lonza社、Wakersville社、MD社、米国)で培養した(実験群)。3日毎に培地を交換して3週間培養した。また、対照群として軟骨細胞の分化誘導培地の代わりに、成長培地を用いて同様の条件で培養した。
骨細胞への分化が可能か否かを調べるために、実施例1-3で得られたeAF-MSCを骨細胞分化誘導培地で培養した。また、対照群として骨細胞分化誘導培地の代わりに、成長培地を用いて同様の条件で培養した。3日ごとに培地を交換して2週間培養した。
脂肪細胞への分化(脂肪生成)の場合、1 x 105個の細胞を6ウェルプレートに分注して、90〜100%の培養密度を示すまで培養した後、脂肪細胞分化誘導培地(低グルコース、10%FBS、100nMデキサメタゾン、10μg/mlのインスリン、0.5 mM 3-イソブチル-1-メチルキサンチン、0.2 mMインドメタシンの条件を持つDMEM培地)で培養した。
Claims (6)
- ウマ科動物の羊水から分離した幹細胞をEGM-2(Endothelial cell Growth Medium-2)培地で培養する第1のステップと
第1のステップで培養した細胞をDMEM(ダルベッコ変法イーグル培地)で培養する第2のステップと、
培養された細胞を回収する第3のステップ
を含み、
次のような特性を示しかつ培養前の幹細胞より均質度が改善されたウマ科動物の羊水由来多分化能幹細胞の製造方法:
(a)ヒトマーカーのCD19、CD20、CD28、CD31、CD34、CD38、CD41a、CD62L、CD62P及びCD200に対して全て陰性の免疫学的特性を示し、ヒトマーカーのCD44、CD90及びCD105に対して全て陽性の免疫的特性を示し、
(b)中胚葉由来細胞に分化する能力を持ち、かつ
(c)未分化の状態で14継代以上培養される能力を持つ。 - 第1のステップにてウマ科動物の羊水から分離された幹細胞が、密度勾配溶液を用いて遠心分離した後、中間層である細胞層から抽出されることが特徴である、請求項1に記載の製造方法。
- 第1のステップが、ウマ科動物の羊水から分離した幹細胞をEGM-2(内皮細胞成長培地-2)培地で付着培養するのが特徴である、請求項1に記載の製造方法。
- 第1のステップにてEGM-2培地にウシ胎児血清(FBS)を添加して培養するのが特徴である、請求項1に記載の製造方法。
- 前記DMEM培地が、ウシ胎児血清(FBS)を含有する低グルコースDMEM培地であることが特徴である、請求項1に記載の製造方法。
- ウマ科動物の羊水を準備する第1のステップと、
前記羊水から、ヒトマーカーのCD19、CD20、CD28、CD31、CD34、CD38、CD41a、CD62L、CD62P及びCD200に対して全て陰性の免疫学的特性を示し、ヒトマーカーのCD44、CD90及びCD105に対して全て陽性の免疫学的特性を示す多分化能幹細胞を、異なる種の間で交差反応を示す前記ヒトマーカーに対する抗体を用いて分離する第2のステップ
を含み、次のような特性を示す均質なウマ科動物の羊水由来多分化能幹細胞の製造方法:
(a)中胚葉由来細胞に分化する能力を持ち、かつ
(b)未分化の状態で14継代以上培養される能力を持つ。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20100088144 | 2010-09-08 | ||
KR10-2010-0088144 | 2010-09-08 | ||
PCT/KR2011/006637 WO2012033352A2 (ko) | 2010-09-08 | 2011-09-07 | 말과동물 양수 유래 다분화능 줄기세포 및 그 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013541329A JP2013541329A (ja) | 2013-11-14 |
JP5833126B2 true JP5833126B2 (ja) | 2015-12-16 |
Family
ID=45811084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013528119A Active JP5833126B2 (ja) | 2010-09-08 | 2011-09-07 | ウマ科動物の羊水由来の多分化能幹細胞及びそれを製造する方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9290739B2 (ja) |
EP (1) | EP2615166B1 (ja) |
JP (1) | JP5833126B2 (ja) |
KR (1) | KR101380561B1 (ja) |
WO (1) | WO2012033352A2 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2927712A1 (en) | 2013-10-24 | 2015-04-30 | Ospedale San Raffaele S.R.L. | Method for the genetic modification of haematopoietic stem and progenitor cells (hspcs) and the use of genetically modified hspcs in gene therapy |
JP6373444B1 (ja) * | 2017-05-10 | 2018-08-15 | 株式会社ホルス | 羊膜由来原料の製造方法、化粧品の製造方法及び健康食品の製造方法 |
KR102092073B1 (ko) * | 2019-07-26 | 2020-03-23 | 주식회사 엠케이바이오텍 | 말과 동물 양수 유래 줄기세포 및 이를 함유하는 근골격계 재생용 세포 치료제 |
KR102226542B1 (ko) * | 2020-03-13 | 2021-03-11 | 주식회사 엠케이바이오텍 | 말과 동물 양수 유래 줄기세포 및 이를 함유하는 근골격계 재생용 세포 치료제 |
EP3909593A1 (en) | 2020-05-15 | 2021-11-17 | Rigshospitalet | Stem cells for treating skin lesions |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120269774A1 (en) | 2006-09-21 | 2012-10-25 | Medistem Laboratories, Inc | Allogeneic stem cell transplants in non-conditioned recipients |
KR100950195B1 (ko) | 2009-03-20 | 2010-03-29 | 서울대학교산학협력단 | Znf281을 발현하는 제대혈 유래 만능 줄기세포의 분리방법 |
-
2011
- 2011-09-07 JP JP2013528119A patent/JP5833126B2/ja active Active
- 2011-09-07 US US13/821,303 patent/US9290739B2/en active Active
- 2011-09-07 KR KR1020110090944A patent/KR101380561B1/ko active IP Right Grant
- 2011-09-07 WO PCT/KR2011/006637 patent/WO2012033352A2/ko active Application Filing
- 2011-09-07 EP EP11823785.8A patent/EP2615166B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2615166A2 (en) | 2013-07-17 |
JP2013541329A (ja) | 2013-11-14 |
WO2012033352A3 (ko) | 2012-06-28 |
KR20120026014A (ko) | 2012-03-16 |
EP2615166B1 (en) | 2018-08-15 |
EP2615166A4 (en) | 2014-03-05 |
US20130230924A1 (en) | 2013-09-05 |
WO2012033352A2 (ko) | 2012-03-15 |
US9290739B2 (en) | 2016-03-22 |
KR101380561B1 (ko) | 2014-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pereira et al. | Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation | |
Pittenger | Mesenchymal stem cells from adult bone marrow | |
CN100480375C (zh) | 人脐带血衍生的非限制性体干细胞(ussc) | |
CA2692634C (en) | Method for isolating and culturing adult stem cells derived from human amniotic epithelium | |
KR100871984B1 (ko) | 태반 조직 유래 다능성 줄기세포 및 이를 함유하는세포치료제 | |
EP1845154A1 (en) | Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same | |
CN101331225B (zh) | 来自脐带血的具有Oct4表达能力的多能成体干细胞及其制备方法 | |
Montemurro et al. | Angiogenic and anti-inflammatory properties of mesenchymal stem cells from cord blood: soluble factors and extracellular vesicles for cell regeneration | |
JPWO2008056779A1 (ja) | 霊長類動物胚性幹細胞の培養及び継代方法、並びにその分化誘導方法 | |
CN104204193A (zh) | 间充质干细胞的培养 | |
JP5833126B2 (ja) | ウマ科動物の羊水由来の多分化能幹細胞及びそれを製造する方法 | |
US20150329827A1 (en) | Muse cells isolation and expansion | |
CN103620023B (zh) | 睾丸体细胞来源的多能干细胞、其制备方法以及包含其的治疗***功能障碍的药物组合物 | |
CN103459590A (zh) | 可由机体的脐带或脂肪组织分离的多能干细胞 | |
JP5388297B2 (ja) | アディポクラスター | |
KR20120006386A (ko) | 1기 태반조직 유래 줄기세포 및 이를 함유하는 세포치료제 | |
CN106661545B (zh) | 制备诱导多能干细胞的方法及由其制备的诱导多能干细胞 | |
US9650604B2 (en) | Equine amniotic membrane-derived mesenchymal stem cells | |
Shah et al. | Types and classification of stem cells | |
Kadivar et al. | Multilineage differentiation activity by the human umbilical vein-derived mesenchymal stem cells | |
KR20140016841A (ko) | 태아연골조직유래 줄기세포원 및 이를 포함하는 세포치료제 | |
KR20130028294A (ko) | 개과 동물의 와튼 젤리-유래 중간엽 줄기세포의 분리 및 특성화 | |
Guenther et al. | The treasury of Wharton's Jelly | |
Chong et al. | Lentiviral vector transduction of fetal mesenchymal stem cells | |
Zhang et al. | Isolation, Culture, Identification and Differentiation of Canine Amniotic Mesenchymal Stem Cells in Vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141119 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150422 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150514 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150624 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150717 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150811 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151014 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151028 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5833126 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |